STOCK TITAN

Axogen (AXGN) director gains 18,867 common shares from RSU vesting

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Axogen, Inc. director THOMAS PAUL acquired 18,867 shares of common stock through the vesting of restricted stock units on June 19, 2026. These 18,867 restricted stock units converted into an equal number of common shares as they vested, reflecting an annual equity grant for service on the Board.

The equity grant was based on a $200,000 valuation as of the original grant date and vested on the one-year anniversary of that date. Following this vesting and conversion, Paul directly holds 32,395 shares of Axogen common stock.

Positive

  • None.

Negative

  • None.
Insider THOMAS PAUL
Role null
Type Security Shares Price Value
Exercise Restricted Stock Units 18,867 $0.00 --
Exercise Common Stock 18,867 $0.00 --
Holdings After Transaction: Restricted Stock Units — 0 shares (Direct, null); Common Stock — 32,395 shares (Direct, null)
Footnotes (1)
  1. This reflects the number of restricted stock units that vested June 19, 2026. Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $200,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.
Shares acquired via RSU vesting 18,867 shares Restricted stock units vested June 19, 2026
Shares owned after transaction 32,395 shares Direct ownership following June 19, 2026 vesting
Equity grant valuation $200,000 Valuation of annual director equity grant at grant date
RSU-to-share ratio 1:1 Each RSU represents right to one share of common stock
Restricted Stock Units financial
"This reflects the number of restricted stock units that vested June 19, 2026."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
contingent right financial
"Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock."
equity grant financial
"Annual equity grant for service as Director on the Axogen, Inc. Board of Directors."
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
THOMAS PAUL

(Last)(First)(Middle)
C/O AXOGEN, INC. 13631 PROGRESS BLVD
SUITE 400

(Street)
ALACHUA FLORIDA 32615

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Axogen, Inc. [ AXGN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/19/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/19/2026M18,867(1)A$032,395D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(2)06/19/2026M18,867 (3) (3)Common Stock18,867$00D
Explanation of Responses:
1. This reflects the number of restricted stock units that vested June 19, 2026.
2. Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
3. Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $200,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.
Remarks:
/s/ Marc Began, as attorney-in-fact for Paul Thomas06/23/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Axogen (AXGN) disclose for director THOMAS PAUL?

Axogen reported that director THOMAS PAUL acquired 18,867 shares of common stock on June 19, 2026. The shares came from vested restricted stock units, not an open-market purchase, and increased his direct holdings to 32,395 shares.

How many Axogen (AXGN) shares did vesting restricted stock units convert into?

The vesting converted 18,867 restricted stock units into 18,867 shares of Axogen common stock. Each restricted stock unit represented a contingent right to receive one share upon vesting, so the share count matches the RSU amount exactly.

What was the value of the equity grant received by Axogen (AXGN) director THOMAS PAUL?

The annual equity grant was based on a $200,000 valuation as of the grant date. This valuation determined the number of restricted stock units awarded, which later vested into 18,867 shares of Axogen common stock on June 19, 2026.

What does the Axogen (AXGN) Form 4 say about director share ownership after the transaction?

After the RSU vesting and conversion, director THOMAS PAUL directly owns 32,395 shares of Axogen common stock. This figure reflects his position immediately following the June 19, 2026 transaction reported in the Form 4 filing.

Was the Axogen (AXGN) insider transaction an open-market buy or routine equity vesting?

The reported activity reflects routine equity vesting, not an open-market buy or sale. Restricted stock units granted for Board service vested on June 19, 2026 and automatically converted into 18,867 common shares at no exercise price.